BTX161

Cat. No.:	HY-120084					
cut. 110	111 120001					
CAS No.:	2052301-24-1					
Molecular Formula:	C ₁₅ H ₁₆ N ₂ O ₃					
Molecular Weight:	272.3					
Target:	Casein Kinase					
Pathway:	Cell Cycle/DNA Damage; Stem Cell/Wnt					
Storage:	Powder	-20°C	3 years			
		4°C	2 years			
	In solvent	-80°C	6 months			
		-20°C	1 month			

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (91.81 mM; ultrasonic and warming and heat to 60°C)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	3.6724 mL	18.3621 mL	36.7242 mL		
		5 mM	0.7345 mL	3.6724 mL	7.3448 mL		
		10 mM	0.3672 mL	1.8362 mL	3.6724 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution						

Description BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2 ^[1] . In Vitro BTX161 (25 µM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA	
Description BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2 ^[1] . In Vitro BTX161 (25 µM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA	
In Vitro BTX161 (25 μM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA	mide in
expression ^[1] . BTX161 (10 μM; 6 hours; MV4-11 cells), on its own, augmented p53 and MDM2 protein expression, yet in combination with THZ1, and particularly with both THZ1 and CDK9, further augmented p53 and induced maximal caspase 3 activation ^[1] .	vith ^{.]} .

Product Data Sheet

0

O

H

0

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Minzel W, et al. Small Molecules Co-targeting CKIa and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018;175(1):171-185.e25.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA